Catalyst Wire Dossier Catalyst Wire Dossier

Antisense therapy targeting the kallikrein-kinin pathway

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Antisense therapy targeting the kallikrein-kinin pathway, covering 2022-09-22 to 2022-09-22. Get the full timeline:

Most recent: Clinical Trial Update: Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19 [Phase 2]

See pricing